uniQure (NASDAQ:QURE) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of uniQure (NASDAQ:QURE) have earned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $23.00.

Several equities research analysts have issued reports on QURE shares. StockNews.com upgraded shares of uniQure to a “sell” rating in a research report on Friday, March 1st. Mizuho reduced their price target on uniQure from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, May 8th. The Goldman Sachs Group cut uniQure from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $63.00 to $8.00 in a research report on Thursday, February 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of uniQure in a research report on Wednesday, May 8th.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James & Associates increased its stake in shares of uniQure by 6.4% in the 4th quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock valued at $354,000 after acquiring an additional 3,145 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in uniQure by 58.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 3,664 shares in the last quarter. Harbor Capital Advisors Inc. increased its stake in uniQure by 21.1% in the fourth quarter. Harbor Capital Advisors Inc. now owns 30,883 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 5,389 shares in the last quarter. Pale Fire Capital SE boosted its position in shares of uniQure by 9.2% during the 4th quarter. Pale Fire Capital SE now owns 65,600 shares of the biotechnology company’s stock worth $444,000 after purchasing an additional 5,500 shares in the last quarter. Finally, Swiss National Bank grew its stake in shares of uniQure by 8.0% in the 3rd quarter. Swiss National Bank now owns 99,400 shares of the biotechnology company’s stock valued at $667,000 after buying an additional 7,400 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Stock Up 0.7 %

QURE stock opened at $4.59 on Friday. The company has a market cap of $222.84 million, a price-to-earnings ratio of -0.74 and a beta of 1.08. uniQure has a twelve month low of $4.25 and a twelve month high of $11.95. The business has a 50 day moving average price of $4.85 and a two-hundred day moving average price of $5.56. The company has a quick ratio of 9.27, a current ratio of 9.39 and a debt-to-equity ratio of 0.70.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.05). The firm had revenue of $8.49 million during the quarter, compared to analyst estimates of $2.58 million. uniQure had a negative net margin of 1,562.22% and a negative return on equity of 121.60%. Analysts anticipate that uniQure will post -4.5 EPS for the current fiscal year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.